Developer docs
API playgroundTry for free, no card

Search company profiles

Optimal Clinical Trials

Full company profile

uuid002se6t

Namestring
Optimal Clinical Trials
Legal namestring
Optimal Clinical Trials Limited
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Optimal Clinical Trials is a New Zealand-based late-phase clinical trial site that executes Phase 1b through Phase 4 studies, with particular depth in vaccines, metabolic disease, and trials involving older adult populations. Founded in 2013 and headquartered in Auckland, the company operates as part of the broader NZCR Group network under NZCR Group Holding Ltd., giving it access to over 450 clinical research professionals across New Zealand and integrated Phase 1 through Phase 4 capability. The site serves global pharmaceutical sponsors and Contract Research Organizations, with named relationships including Pfizer, AstraZeneca, Roche, Eli Lilly, Moderna, GSK, AbbVie, and Syneos Health, and has achieved multiple global top-recruitment rankings across therapeutic areas.

The company's core operational asset is its access to approximately 153,000 patient records representing roughly 75% of New Zealand's primary care database, which materially accelerates recruitment and underpins its top-recruitment performance. Quality systems are anchored by ISO 9001 certification and multiple successful FDA audits, and a 2024 Net Promoter Score of 97 indicates exceptional satisfaction among sponsors and participants. The site has expanded beyond Auckland with a Christchurch location, providing national coverage across New Zealand's two largest population centers.

Optimal Clinical Trials generates revenue through project-based clinical trial service delivery, charging sponsors and CROs per-patient and per-trial fees for protocol execution, recruitment, and site management. Additional revenue attractiveness is supported by New Zealand's government-approved R&D incentive framework, which provides 15-43% tax advantages to research sponsors conducting studies in the country. The company has been recognized on the Deloitte Fast 50 index for revenue growth, reflecting strong historical expansion. Its primary customer segment is large-cap global pharma and top-tier CROs, with no visible exposure to SMB or long-tail sponsors.

Short descriptiontext

Optimal Clinical Trials is a New Zealand-based late-phase (Phase 1b-4) clinical trial site executing vaccine, metabolic, and older-adult studies for global pharma sponsors and CROs, leveraging access to roughly 75% of New Zealand's primary care patient database.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAuckland, New Zealand
HQ citystring
Auckland
HQ countrystring
New Zealand
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial services, late-phase research, vaccine trials, patient recruitment, clinical research site
Industry4 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Trial Services for Sponsors and CROs
TypeProfessional Services
Description

The company conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and CROs. Revenue is generated through contractual agreements for conducting clinical research studies, including participant recruitment, data collection, and regulatory compliance services.

optimalclinicaltrials.com
2Government R&D Incentives
TypeLicensing Royalties
Description

As a government-approved R&D incentives provider, the company can access R&D tax benefits, providing 15-43% Research & Development tax advantage for sponsors running trials in New Zealand

optimalclinicaltrials.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Optimal Clinical Trials is a New Zealand-based late-phase clinical research organization that conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and contract research organizations (CROs). The company specializes in vaccine trials, metabolic studies (obesity, diabetes), older adult research, and dermatology studies, offering rapid startup (4-6 weeks), large-scale patient recruitment, retention management, and quality data delivery across research sites in Auckland and Christchurch.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 95-100% participant retention rates across studies
+5 more records
Product overview1 text field

Optimal Clinical Trials operates as a late-phase clinical research organization offering a unified service portfolio centered on clinical trial execution. The core offering comprises Phase 1b-3 clinical trial services spanning vaccine trials, metabolic studies, and older adult research programs. Supporting capabilities include a large patient recruitment database with access to 75% of New Zealand's primary care database, rescue site services for underperforming studies, and specialized dermatology research. The company delivers integrated services including rapid startup, patient recruitment, retention optimization, and quality data collection through its network of research sites in Auckland and Christchurch.

Product and service7 records
1Late-Phase Clinical Trial Services
CategoryClinical Trial Services
Description

Comprehensive Phase 1b-3 clinical trial execution services including study design feedback, patient recruitment, retention management, and data collection for pharmaceutical sponsors and CROs.

2Vaccine Trial Services
CategoryClinical Trial Services
Description

Specialized vaccine clinical trial services including rapid start-up, high recruitment, and quality data delivery for influenza, COVID-19, RSV, and combination vaccine programs.

3Metabolic Trial Services
CategoryClinical Trial Services
Description

Clinical trial services for metabolic conditions including obesity, diabetes, and weight management studies, leveraging access to relevant patient populations.

4Older Adult Clinical Trial Services
CategoryClinical Trial Services
Description

Specialized clinical research services targeting older adult populations with focus on conditions prevalent in aging, including respiratory diseases and metabolic disorders.

5Rescue Site Services
CategoryClinical Trial Services
Description

Clinical trial rescue services to help sponsors recover underperforming studies through rapid startup, high recruitment, and quality data delivery.

6Atopic Dermatitis Research Services
CategoryClinical Trial Services
Description

Specialized dermatology clinical trial services including expertise in EASI, Hanifin and Rajka criteria, IGA assessments, and experience with biologics including dupilumab trials.

7Patient Recruitment Database Access
CategoryPatient Recruitment Services
Description

Access to diverse patient pools including over 153,000 potential participants, 1,300 atopic dermatitis patients, and coverage of approximately 75% of New Zealand's primary care database.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Optimal is part of NZCR Group - Australasia's largest clinical trials group offering complete Phase 1-4 capability. This partnership enables Optimal to offer end-to-end clinical trial services from early phase through late-phase studies.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Optimal was chosen as a Syneos Health Catalyst Site. This partnership expands Syneos Health's clinical trial capabilities in New Zealand, with collaboration focusing on CNS and Vaccines therapeutic areas.

3Greenlane Medical Specialists
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Greenlane Medical Specialists Group (GLMS), a specialist organization of over 25 medical consultants covering 17 therapeutic areas. GLMS provides specialist expertise for feasibility, patient identification and recruitment, and specialist input for study procedures.

optimalclinicaltrials.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Served as rescue site for Equillium Bio's Alopecia Areata clinical study, delivering 200% of recruitment target with 100% retention rate.

5Cue Health
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnered with Cue Health for COVID-19 and Flu Nasal Testing Device Clinical Study. Optimal achieved First Patient-In globally for this study.

optimalclinicaltrials.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with Dr Falk Pharma International for a clinical study researching a potential new treatment for coeliac disease, testing effectiveness in reducing symptoms and healing intestinal lining.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical research site for GSK's Arexvy (RSV vaccine), contributing to FDA approval - the world's first RSV vaccine for older adults. Worked with PPD as CRO partner on this pivotal study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Key research site for CLEAR Outcomes trials studying Bempedoic acid for cardiovascular risk reduction. Results presented at ACC.23 and published in NEJM. Worked with IQVIA as CRO partner.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnered on multiple vaccine trials including Phase 2 COVID-Influenza Combination (CIC) vaccine study. Novavax announced positive results from the trial evaluating safety and immune responses.

10New Zealand Story Group
Strategic tierMinorTypeGTM or Marketing Partner
Description

Featured by New Zealand Story Group to share the company's story of contributing to life-changing medical discoveries since 2013.

optimalclinicaltrials.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO that has designated Optimal as a Catalyst Site for CNS and Vaccines. Comparable as a broader incumbent offering site network services that partially overlap with Optimal's late-phase offerings, though at much larger global scale.

TypeBroad incumbent
Description

Global CRO named as a partner in Optimal's customer roster. Comparable broad incumbent with late-phase clinical trial services that overlap with Optimal's offerings.

TypeBroad incumbent
Description

Global CRO listed as an Optimal partner. Comparable as a broad incumbent offering late-phase site management and full-service clinical research that competes for the same sponsor budgets.

TypeBroad incumbent
Description

Global clinical research organization named as an Optimal partner. Comparable broad incumbent offering late-phase site services that overlap with Optimal's core business.

TypeBroad incumbent
Description

Global CRO that partnered with Optimal on GSK's Arexvy RSV vaccine program. Comparable broad incumbent in late-phase clinical research serving the same sponsor base.

TypeBroad incumbent
Description

Global CRO that partners with Optimal as a research site. Comparable as a broad incumbent that both competes for and sources late-phase trial work from independent sites like Optimal.

TypeBroad incumbent
Description

Global mid-sized CRO listed as an Optimal partner. Comparable in late-phase trial execution with overlapping therapeutic-area expertise in metabolic, vaccines, and CNS.

TypeDirect peer
Description

Asia-Pacific-focused CRO that both partners with and competes against Optimal for sponsor trial allocation. Highly comparable in APAC late-phase site services and is named as a CRO partner in Optimal's customer roster.

TypeRegional player
Description

Australia-based early- and late-phase clinical trials site in Perth. Comparable regional player offering sponsor-facing late-phase trial services across Australasia, though operating from a different geography within the same broader market.

TypeDirect peer
Description

Optimal's parent group affiliate operating early-phase (Phase 1) trials in Australasia. Direct peer given shared ownership, overlapping investigator network, and complementary Phase 1-4 coverage for the same sponsor base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers29 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optimal Clinical Trials

Clinical Research Servicesoptimalclinicaltrials.com

Optimal Clinical Trials is a New Zealand-based late-phase (Phase 1b-4) clinical trial site executing vaccine, metabolic, and older-adult studies for global pharma sponsors and CROs, leveraging access to roughly 75% of New Zealand's primary care patient database.

What Optimal Clinical Trials does

Optimal Clinical Trials is a New Zealand-based late-phase clinical trial site that executes Phase 1b through Phase 4 studies, with particular depth in vaccines, metabolic disease, and trials involving older adult populations. Founded in 2013 and headquartered in Auckland, the company operates as part of the broader NZCR Group network under NZCR Group Holding Ltd., giving it access to over 450 clinical research professionals across New Zealand and integrated Phase 1 through Phase 4 capability. The site serves global pharmaceutical sponsors and Contract Research Organizations, with named relationships including Pfizer, AstraZeneca, Roche, Eli Lilly, Moderna, GSK, AbbVie, and Syneos Health, and has achieved multiple global top-recruitment rankings across therapeutic areas.

The company's core operational asset is its access to approximately 153,000 patient records representing roughly 75% of New Zealand's primary care database, which materially accelerates recruitment and underpins its top-recruitment performance. Quality systems are anchored by ISO 9001 certification and multiple successful FDA audits, and a 2024 Net Promoter Score of 97 indicates exceptional satisfaction among sponsors and participants. The site has expanded beyond Auckland with a Christchurch location, providing national coverage across New Zealand's two largest population centers.

Optimal Clinical Trials generates revenue through project-based clinical trial service delivery, charging sponsors and CROs per-patient and per-trial fees for protocol execution, recruitment, and site management. Additional revenue attractiveness is supported by New Zealand's government-approved R&D incentive framework, which provides 15-43% tax advantages to research sponsors conducting studies in the country. The company has been recognized on the Deloitte Fast 50 index for revenue growth, reflecting strong historical expansion. Its primary customer segment is large-cap global pharma and top-tier CROs, with no visible exposure to SMB or long-tail sponsors.

Optimal Clinical Trials firmographics

Firmographics
Name
Optimal Clinical Trials
Legal name
Optimal Clinical Trials Limited
Website
https://optimalclinicaltrials.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Optimal Clinical Trials is a New Zealand-based late-phase (Phase 1b-4) clinical trial site executing vaccine, metabolic, and older-adult studies for global pharma sponsors and CROs, leveraging access to roughly 75% of New Zealand's primary care patient database.
Ownership category
akta.pro rank

Optimal Clinical Trials industry classification

Industry
Product category
Clinical Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical trial services
  • Late-phase research
  • Vaccine trials
  • Patient recruitment
  • Clinical research site

Where Optimal Clinical Trials is headquartered

Location

Headquarters

HQ city
Auckland
HQ country
New Zealand
HQ region
Oceania

Offices3 records

Markets served

Optimal Clinical Trials business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Clinical Trial Services for Sponsors and CROs: The company conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and CROs. Revenue is generated through contractual agreements for conducting clinical research studies, including participant recruitment, data collection, and regulatory compliance services.
  2. Government R&D Incentives: As a government-approved R&D incentives provider, the company can access R&D tax benefits, providing 15-43% Research & Development tax advantage for sponsors running trials in New Zealand

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Optimal Clinical Trials product offering

Product offering

Core offering

Optimal Clinical Trials is a New Zealand-based late-phase clinical research organization that conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and contract research organizations (CROs). The company specializes in vaccine trials, metabolic studies (obesity, diabetes), older adult research, and dermatology studies, offering rapid startup (4-6 weeks), large-scale patient recruitment, retention management, and quality data delivery across research sites in Auckland and Christchurch.

Product overview

Optimal Clinical Trials operates as a late-phase clinical research organization offering a unified service portfolio centered on clinical trial execution. The core offering comprises Phase 1b-3 clinical trial services spanning vaccine trials, metabolic studies, and older adult research programs. Supporting capabilities include a large patient recruitment database with access to 75% of New Zealand's primary care database, rescue site services for underperforming studies, and specialized dermatology research. The company delivers integrated services including rapid startup, patient recruitment, retention optimization, and quality data collection through its network of research sites in Auckland and Christchurch.

Differentiator

Problem solved

Functional benefit

Products and services

  • Late-Phase Clinical Trial Services Comprehensive Phase 1b-3 clinical trial execution services including study design feedback, patient recruitment, retention management, and data collection for pharmaceutical sponsors and CROs.
  • Vaccine Trial Services Specialized vaccine clinical trial services including rapid start-up, high recruitment, and quality data delivery for influenza, COVID-19, RSV, and combination vaccine programs.
  • Metabolic Trial Services Clinical trial services for metabolic conditions including obesity, diabetes, and weight management studies, leveraging access to relevant patient populations.
  • Older Adult Clinical Trial Services Specialized clinical research services targeting older adult populations with focus on conditions prevalent in aging, including respiratory diseases and metabolic disorders.
  • Rescue Site Services Clinical trial rescue services to help sponsors recover underperforming studies through rapid startup, high recruitment, and quality data delivery.
  • Atopic Dermatitis Research Services Specialized dermatology clinical trial services including expertise in EASI, Hanifin and Rajka criteria, IGA assessments, and experience with biologics including dupilumab trials.
  • Patient Recruitment Database Access Access to diverse patient pools including over 153,000 potential participants, 1,300 atopic dermatitis patients, and coverage of approximately 75% of New Zealand's primary care database.

Quantifiable outcome

  • 95-100% participant retention rates across studies
  • +5 more outcomes

Companies that use Optimal Clinical Trials

Customer profile

Named customers29 records

Segments6 records

Ideal customer profiles3 records

Optimal Clinical Trials technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Optimal Clinical Trials partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • NZCR Group (New Zealand Clinical Research)coreStrategic or Co-development PartnerOptimal is part of NZCR Group - Australasia's largest clinical trials group offering complete Phase 1-4 capability. This partnership enables Optimal to offer end-to-end clinical trial services from early phase through late-phase studies.
  • Syneos HealthflagshipStrategic or Co-development PartnerOptimal was chosen as a Syneos Health Catalyst Site. This partnership expands Syneos Health's clinical trial capabilities in New Zealand, with collaboration focusing on CNS and Vaccines therapeutic areas.
  • Greenlane Medical SpecialistscoreStrategic or Co-development PartnerPartnership with Greenlane Medical Specialists Group (GLMS), a specialist organization of over 25 medical consultants covering 17 therapeutic areas. GLMS provides specialist expertise for feasibility, patient identification and recruitment, and specialist input for study procedures.
  • Equillium BiominorStrategic or Co-development PartnerServed as rescue site for Equillium Bio's Alopecia Areata clinical study, delivering 200% of recruitment target with 100% retention rate.
  • Cue HealthminorStrategic or Co-development PartnerPartnered with Cue Health for COVID-19 and Flu Nasal Testing Device Clinical Study. Optimal achieved First Patient-In globally for this study.
  • Dr Falk PharmaminorStrategic or Co-development PartnerPartnership with Dr Falk Pharma International for a clinical study researching a potential new treatment for coeliac disease, testing effectiveness in reducing symptoms and healing intestinal lining.
  • GSKcoreStrategic or Co-development PartnerClinical research site for GSK's Arexvy (RSV vaccine), contributing to FDA approval - the world's first RSV vaccine for older adults. Worked with PPD as CRO partner on this pivotal study.
  • Esperion TherapeuticscoreStrategic or Co-development PartnerKey research site for CLEAR Outcomes trials studying Bempedoic acid for cardiovascular risk reduction. Results presented at ACC.23 and published in NEJM. Worked with IQVIA as CRO partner.
  • NovavaxcoreStrategic or Co-development PartnerPartnered on multiple vaccine trials including Phase 2 COVID-Influenza Combination (CIC) vaccine study. Novavax announced positive results from the trial evaluating safety and immune responses.
  • New Zealand Story GroupminorGTM or Marketing PartnerFeatured by New Zealand Story Group to share the company's story of contributing to life-changing medical discoveries since 2013.

Scale indicators11 records

Recent moves8 records

Expansion highlights4 records

Optimal Clinical Trials competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Global CRO that has designated Optimal as a Catalyst Site for CNS and Vaccines. Comparable as a broader incumbent offering site network services that partially overlap with Optimal's late-phase offerings, though at much larger global scale.
  • Parexel: Global CRO named as a partner in Optimal's customer roster. Comparable broad incumbent with late-phase clinical trial services that overlap with Optimal's offerings.
  • ICON plc: Global CRO listed as an Optimal partner. Comparable as a broad incumbent offering late-phase site management and full-service clinical research that competes for the same sponsor budgets.
  • Fortrea: Global clinical research organization named as an Optimal partner. Comparable broad incumbent offering late-phase site services that overlap with Optimal's core business.
  • PPD (Thermo Fisher): Global CRO that partnered with Optimal on GSK's Arexvy RSV vaccine program. Comparable broad incumbent in late-phase clinical research serving the same sponsor base.
  • IQVIA: Global CRO that partners with Optimal as a research site. Comparable as a broad incumbent that both competes for and sources late-phase trial work from independent sites like Optimal.
  • Medpace: Global mid-sized CRO listed as an Optimal partner. Comparable in late-phase trial execution with overlapping therapeutic-area expertise in metabolic, vaccines, and CNS.

Direct peers

  • Novotech: Asia-Pacific-focused CRO that both partners with and competes against Optimal for sponsor trial allocation. Highly comparable in APAC late-phase site services and is named as a CRO partner in Optimal's customer roster.
  • New Zealand Clinical Research (NZCR): Optimal's parent group affiliate operating early-phase (Phase 1) trials in Australasia. Direct peer given shared ownership, overlapping investigator network, and complementary Phase 1-4 coverage for the same sponsor base.

Regional players

  • Linear Clinical Research: Australia-based early- and late-phase clinical trials site in Perth. Comparable regional player offering sponsor-facing late-phase trial services across Australasia, though operating from a different geography within the same broader market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Optimal Clinical Trials social profiles

Digital presence

Optimal Clinical Trials compliance and trust

Trust signal

Compliance2 records

Optimal Clinical Trials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optimal Clinical Trials leadership team

Management profile

Number of profiles

Profiles11 records

Optimal Clinical Trials funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optimal Clinical Trials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optimal Clinical Trials

What does Optimal Clinical Trials do?

Optimal Clinical Trials is a New Zealand-based late-phase clinical research organization that conducts Phase 1b-4 clinical trials on behalf of pharmaceutical sponsors, biotech companies, and contract research organizations (CROs). The company specializes in vaccine trials, metabolic studies (obesity, diabetes), older adult research, and dermatology studies, offering rapid startup (4-6 weeks), large-scale patient recruitment, retention management, and quality data delivery across research sites in Auckland and Christchurch.

Is Optimal Clinical Trials a public or private company?

Optimal Clinical Trials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Optimal Clinical Trials founded?

Optimal Clinical Trials was founded in 2013. It employs 51 to 100 people.

Where is Optimal Clinical Trials based?

Optimal Clinical Trials is headquartered in Auckland, New Zealand, in the Oceania region.

How does Optimal Clinical Trials make money?

Two revenue lines are on record. Clinical Trial Services for Sponsors and CROs are the primary driver. The others are government R&D Incentives.

Who are Optimal Clinical Trials's main competitors?

Broad incumbents on record are Syneos Health, Parexel, ICON plc, Fortrea, PPD (Thermo Fisher), IQVIA and Medpace. Direct peers are Novotech and New Zealand Clinical Research (NZCR). Linear Clinical Research is listed as a regional player.

Does Optimal Clinical Trials have an API?

No public API is recorded for Optimal Clinical Trials.

What industry is Optimal Clinical Trials in?

Optimal Clinical Trials's product category is Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals